Advertisement

Topics

Astellas Pharma GmbH Company Profile

13:28 EST 23rd November 2017 | BioPortfolio

Aktuelle Studie belegt: Fluvastatin senkt die Blutfette sicher und effektiv unabhängig von der Tageszeit Dresden, 6. Oktober 2005. Die Retard-Formulierung von Fluvastatin wirkt effektiv und sicher, auch unabhängig vom Zeitpunkt der Einnahme. Das Präparat ermöglicht eine optimale Blutfetteinstellung über 24 Stunden, ganz gleich, zu welchem Zeitpunkt des Tages - morgens oder abends - das Medikament eingenommen wird. Dies fördert die Compliance, da der Zeitpunkt der Tabletteneinnahme individuell an den jeweiligen Patienten angepasst werden kann. Ein Vorteil für den Arzt und den Patienten. Zu diesem Ergebnis kommt eine neue Studie des Klinischen Instituts für Medizinische und Chemische Labordiagnostik der Universität Graz, die erstmals am 6. Oktober auf der Herbsttagung der Kardiologen in Dresden präsentiert wurde

Location

Postfach 80 06 28
Munich
München
D-81606
Germany

Contact

Phone: (089) 45 44 - 01
Fax: (089) 45 44 - 13 29
Email: info@de.astellas.com


News Articles [883 Associated News Articles listed on BioPortfolio]

Astellas Supports the Northern Kyushu Heavy Rain Relief Efforts

Tokyo, July 13, 2017– Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) would like to express our deepest sympathy to the victims of the heavy rain hit to No...

ABPI Extends Suspension of Astellas UK

The Association of the British Pharmaceutical Industry (ABPI) has suspended Astellas UK’s membership for a further 12 months from Jun. 24 because of several serious breaches of its Code of Pract...

Promotions at Astellas in the USA

Japanese pharma major Astellas Pharma today announced two senior-level promotions in its Marketing Strategy…

LTL Pharma Succeeds Marketing Approval for "Nivadil® Tablets", "Solantal® Tablets" and "Lowgan® Tablets", and isTransferred Distribution Rights in Japan

Tokyo (Japan), August 1, 2017 –LTL Pharma Co., Ltd. (Representative Director, Chairman: Sansei Oka, Representative Director, President: Jiro Mizukawa, “LTL Pharma”) and Astellas Ph...

Astellas Pharma Inc. Strategy, SWOT and Corporate Finance Report [Report Updated: 02082017] Prices from USD $175

Astellas Pharma Inc. Strategy, SWOT and Corporate Finance ReportSummaryAstellas Pharma Inc. Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. Th...

Astellas and Universal Cells Enter Collaboration Utilizing Universal Donor Cell Technology

TOKYO, Oct. 19, 2017 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Universal Cells, Inc. (CEO: Claudia Mitchell, “Unive...

Astellas AML Inhibitor Granted Orphan Drug Designation

NewsU.S. FDA grants orphan-drug designation to Astellas for development of FLT3 inhibitor gilteritinib in acute myeloid leukemia.

Supplemental NDA for Astellas' Overactive Bladder Treatment Reviewed by FDA

NewsU.S. FDA accepts for review Astellas' supplemental New Drug Application for mirabegron for use in combination with solifenacin succinate 5 mg for the treatment of overactive bladder.

Drugs and Medications [277 Associated Drugs and Medications listed on BioPortfolio]

Vesicare [Astellas Pharma Technologies, Inc.]

These highlights do not include all the information needed to use VESIcare safely and effectively. See full prescribing information for VESIcare. VESIcare (solifenacin succinate) tablets Initial U.S. ...

Alcohol prep pad [Büttner-Frank GmbH]

La prairie switzerland [Juvena Produits de Beaute GMBH]

Package.Label Principle Display Panel

Fluoride [Libertas Pharma, Inc.]

Fluoride Chewable Tablets 0.5 mg

Fluoride [Libertas Pharma, Inc.]

Fluoride Chewable Tablets 1 mg

PubMed Articles [38 Associated PubMed Articles listed on BioPortfolio]

Delivering advanced therapies: The big pharma approach.

After two decades of focused development and some recent clinical successes, cell and gene therapy (CGT) is emerging as a promising approach to personalized medicines. Genetically engineered cells as ...

Bioanalytical outsourcing: transitioning from Pharma to CRO.

Clinical Trials Series - Large Pharma.

AI-powered drug discovery captures pharma interest.

Arkansas execution proceeds as pharma companies lose battle to stop use of their drugs.

Clinical Trials [111 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Linagliptin from Prevaglip 5 mg tablets(Eva pharma for Pharmaceuticals & Me...

Bioequivalence Study of Tacrolimus 5 mg Capsule Under Fed Condition

The objective of the study is to demonstrate bioequivalence between Test Product (A): Tacrolimus Capsules 5 mg, manufactured by Panacea Biotec Limited, India and the corresponding Referenc...

Bioequivalence Study of Tacrolimus 1 mg Capsule Under Fed Condition

The objective of the study is to demonstrate bioequivalence between Test Product (A): Tacrolimus Capsules 1 mg, manufactured by Panacea Biotec Limited, India and the corresponding Referenc...

Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial

The purpose of the study is to provide access to continued treatment for subjects who participated in other Astellas sponsored ASP2215 trials and for whom the Investigator feels the subjec...

Bioequivalence Study of Tacrolimus 1 mg Capsule Under Fasting Condition

The objective of the study is to demonstrate bioequivalence between Test Product (A): Tacrolimus Capsules 1 mg, manufactured by Panacea Biotec Limited, India and the corresponding Referenc...

Companies [1226 Associated Companies listed on BioPortfolio]

Astellas Pharma Canada, Inc.

Astellas Pharma Europe Ltd., located in the UK, is the European Headquarters of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the he...

Astellas Pharma Global Development

Astellas Pharma Global Development, located in Deerfield, Illinois, is a group company of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of peo...

Astellas Pharma Inc.

Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals...

Astellas Pharma Europe Ltd.

Astellas Pharma Europe Ltd., located in the UK, is a European subsidiary of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around...

Potenza Therapeutics, Inc.

Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and rel...

More Information about "Astellas Pharma GmbH" on BioPortfolio

We have published hundreds of Astellas Pharma GmbH news stories on BioPortfolio along with dozens of Astellas Pharma GmbH Clinical Trials and PubMed Articles about Astellas Pharma GmbH for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Astellas Pharma GmbH Companies in our database. You can also find out about relevant Astellas Pharma GmbH Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record